Filtered By:
Condition: Multiple Sclerosis
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 1656 results found since Jan 2013.
Could saccadic function be a useful marker of stroke recovery?
There is no pharmacological therapy presently available to improve the long-term recovery from acute ischaemic stroke. Either there hasn't yet been a suitable treatment trialled, or the tools for measuring recovery have not been sensitive enough. It is critical therefore to continue to search for robust objective markers of stroke recovery in parallel with the push for drug discovery. Can saccade measures provide such a marker? Dong et al report that in a limited number of mild stroke patients, saccadic parameters that probe cognitive function, especially errors of inhibition during antisaccade and memory-guided paradigms,...
Source: Journal of Neurology, Neurosurgery and Psychiatry - February 15, 2013 Category: Neurosurgery Authors: Anderson, T. Tags: Other rehabilitative therapies, Genetics, Immunology (including allergy), Brain stem / cerebellum, Drugs: CNS (not psychiatric), Movement disorders (other than Parkinsons), Multiple sclerosis, Parkinson's disease, Spinal cord, Stroke, Ophthalmology, Memor Source Type: research
Acorda's MS Drug Ampyra Helps Stroke Patients Walk
An Acorda Therapeutics drug, Ampyra (dalfampridine), which helps people with multiple sclerosis walk, also helps stroke patients who cannot walk, the company announced. In a proof-of- concept Phase II study, Ampyra (dalfampridine extended release 10mg tablets) significantly improved walking in patients with post-stroke deficits. Post-stroke deficits include impaired walking, motor and sensory function, as well as manual dexterity - collectively known as chronic neurological deficits. These deficits often persist in stroke victims. Ron Cohen, M.D...
Source: Health News from Medical News Today - April 15, 2013 Category: Consumer Health News Tags: Stroke Source Type: news
Glatiramer acetate does not protect from acute ischemic stroke in mice
Conclusions
Glatiramer acetate failed to protect from acute ischemic stroke in our hands. Further studies are needed to assess the true therapeutic potential of glatiramer acetate and related immunomodulators in brain ischemia.
Source: Experimental and Translational Stroke Medicine - February 27, 2014 Category: Neurology Source Type: research
Interferon-{beta} Modulates Inflammatory Response in Cerebral Ischemia Stroke
Conclusions
Our results demonstrate that IFNβ exerts a protective effect against ischemic stroke through its anti-inflammatory properties and suggest that IFNβ is a potential therapeutic agent, targeting the reperfusion damage subsequent to the treatment with tissue plasminogen activator.
Source: JAHA:Journal of the American Heart Association - January 8, 2016 Category: Cardiology Authors: Kuo, P.-C., Scofield, B. A., Yu, I.-C., Chang, F.-L., Ganea, D., Yen, J.-H. Tags: Inflammation, Translational Studies, Treatment, Ischemic Stroke Source Type: research
Natalizumab Versus Placebo in Patients with Acute Ischemic Stroke (AIS): Results from ACTION, a Multicenter, Double-Blind, Placebo-Controlled, Randomized Phase 2 Clinical Trial (S7.005)
CONCLUSIONS: A single dose of natalizumab administered up to 9 hours after stroke onset did not reduce focal infarct volume growth, but natalizumab appeared to be associated with important functional outcome improvements sustained over 90 days. Further natalizumab studies for AIS are warranted. Support: Biogen.Disclosure: Dr. Elkins holds stock and/or stock options in Biogen, which sponsored research in which Dr. Elkins was involved as a researcher. Dr. Elkind has received personal compensation in and editorial capacity for serving as an Associate Editor of the journal Neurology. Dr. Veltkamp has received research support ...
Source: Neurology - April 3, 2016 Category: Neurology Authors: Elkins, J., Elkind, M., Veltkamp, R., Montaner, J., Johnston, S., Singhal, A., Becker, K., Lansberg, M., Chang, I., Tang, W., Gheuens, S., Mehta, L. Tags: Stroke Clinical Trials Source Type: research
Measuring arm function early after stroke: is the DASH good enough?
Conclusions
RMT methods identified limitations missed by CTT and indicate areas for improvement of the DASH as an upper limb measure for acute stroke. Findings, similar to those identified in multiple sclerosis, highlight the need for scales to have strong conceptual underpinnings, with their development and modification guided by sophisticated psychometric methods.
Source: Journal of Neurology, Neurosurgery and Psychiatry - May 12, 2016 Category: Neurosurgery Authors: Baker, K., Barrett, L., Playford, E. D., Aspden, T., Riazi, A., Hobart, J. Tags: Immunology (including allergy), Multiple sclerosis, Stroke Cerebrovascular disease Source Type: research
Glatiramer acetate does not protect from acute ischemic stroke in mice
ConclusionsGlatiramer acetate failed to protect from acute ischemic stroke in our hands. Further studies are needed to assess the true therapeutic potential of glatiramer acetate and related immunomodulators in brain ischemia.
Source: Experimental and Translational Stroke Medicine - February 27, 2014 Category: Neurology Source Type: research
Dalfampridine Improves Sensorimotor Function in Rats With Chronic Deficits After Middle Cerebral Artery Occlusion Basic Sciences
Conclusions—
Dalfampridine improves sensorimotor function in the rat permanent middle cerebral artery occlusion model. Dalfampridine extended-release tablets (prolonged release fampridine outside the United States) are used to improve walking in patients with multiple sclerosis, and these preclinical data provide a strong rationale for examining the potential of dalfampridine to treat chronic stable deficits in stroke patients.
Clinical Trial Registration—
URL: http://www.clinicaltrials.gov. Unique identifier: NCT01605825
Source: Stroke - June 24, 2013 Category: Neurology Authors: Iaci, J. F., Parry, T. J., Huang, Z., Finklestein, S. P., Ren, J., Barrile, D. K., Davenport, M. D., Wu, R., Blight, A. R., Caggiano, A. O. Tags: Animal models of human disease, Other Stroke Treatment - Medical Basic Sciences Source Type: research
Misdiagnosis in Young Patients with Ischemic Stroke (P7.122)
Conclusions It is essential to increase awareness that young patients with stroke may present to emergency department with minor symptoms of artery dissection mainly involving the posterior circulation and lacking cardiovascular risk factors.Disclosure: Dr. Leon has nothing to disclose. Dr. Pantiu has nothing to disclose. Dr. Quiroga has nothing to disclose. Dr. Bonardo has nothing to disclose. Dr. Uribe has nothing to disclose. Dr. Mazziotti has received research support from Shire Pharmaceuticals Group. Dr. Zinnerman has nothing to disclose. Dr. Martinez has nothing to disclose. Dr. Sotelo has nothing to disclose. Dr. Ju...
Source: Neurology - April 8, 2015 Category: Neurology Authors: Leon, L., Pantiu, F., Quiroga, J., Bonardo, P., Uribe, C., Mazziotti, J., Zinnerman, A., Martinez, A., Sotelo, A., Jure, L., Nofal, P., Bendersky, E., Sposato, L. A., Riccio, P., Reisin, R., Fernandez Pardal, M. Tags: Cerebrovascular Disease and Interventional Neurology: Stroke in Young Source Type: research
Anxiety in Patients With Acute Ischemic Stroke: Risk Factors and Effects on Functional Status
Conclusion: Depressive symptoms are the major correlates of PSA while more severe PSA is associated with poorer ADL and health-related QOL. Acute lesions involving CHWM may correlate with PSA in ischemic stroke patients with mild-to-moderate neurologic deficits, supporting a lesion-location hypothesis in PSA.IntroductionAnxiety is prevalent after stroke and occurs in about one-quarter of stroke survivors (1, 2). Poststroke anxiety (PSA) may have a negative impact on quality of life (QOL) of stroke survivors, affecting their rehabilitation (3). Furthermore, one prospective study found that severe anxiety symptoms were assoc...
Source: Frontiers in Psychiatry - April 16, 2019 Category: Psychiatry Source Type: research
Quick magnesium treatment fails to improve stroke outcomes, but study has silver lining
In the first study of its kind, a consortium led by UCLA physicians found that giving stroke patients intravenous magnesium within an hour of the onset of symptoms does not improve stroke outcomes.
However, the 8-year trial did find that with the help of paramedics in the field, intravenous medications can frequently be administered to stroke victims within that so-called "golden hour," during which they have the best chance to survive and avoid debilitating, long-term neurological damage.
The latter finding is a "game-changer," said Dr. Jeffrey Saver, director of the UCLA Stroke Center and a professor of ...
Source: UCLA Newsroom: Health Sciences - February 13, 2014 Category: Universities & Medical Training Source Type: news
Modafinil for the Improvement of Patient Outcomes Following Traumatic Brain Injury
Conclusion. Modafinil is a central nervous system stimulant with well-established effectiveness in the treatment of narcolepsy and shift-work sleep disorder. There is conflicting evidence about the benefits of modafinil in the treatment of fatigue and EDS secondary to TBI. One randomized, controlled study states that modafinil does not significantly improve patient wakefulness, while another concludes that modafinil corrects EDS but not fatigue. An observational study provides evidence that modafinil increases alertness in fatigued patients with past medical history of brainstem diencephalic stroke or multiple sclerosis. ...
Source: Innovations in Clinical Neuroscience - April 1, 2018 Category: Neuroscience Authors: ICNS Online Editor Tags: Current Issue Review excessive daytime sleep fatigue head injury modafinil stroke TBI traumatic brain injury Source Type: research
Can we distinguish stroke and stroke mimics via red cell distribution width in young patients?
CONCLUSIONS: Red cell distribution width is a promising, rapid, easy and inexpensive parameter to distinguish young stroke from stroke mimics (such as epilepsy and MS) in young patients.
PMID: 26528336 [PubMed]
Source: Archives of Medical Science - November 4, 2015 Category: Biomedical Science Tags: Arch Med Sci Source Type: research
Stroke Subtypes and Risk Factors in Saudi Arabia (P1.124)
CONCLUSION: Non-cardioembolic disease was the overwhelming stroke mechanism in this middle-eastern cohort with only 4[percnt] of patients have cardioembolic stroke, in comparison to roughly 20[percnt] reported in Western cohorts. In part, these differences may be explained by deficient prolonged cardiac monitoring. However the high prevalence of atherothrombotic risk factors and overrepresentation of non-cardioembolic stroke suggests a need to optimize atherothrombotic stroke risk factor management within our populationDisclosure: Dr. Al Harbi has nothing to disclose. Dr. Shoamanesh has nothing to disclose.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Al Harbi, A., Shoamanesh, A. Tags: Cerebrovascular Disease: Epidemiology Source Type: research
Immune cell trafficking across the barriers of the central nervous system in multiple sclerosis and stroke
This article is part of a Special Issue entitled: Neuro inflammation: A common denominator for stroke, multiple sclerosis and Alzheimer's disease
Source: Biochimica et Biophysica Acta (BBA) Molecular Basis of Disease - October 25, 2015 Category: Molecular Biology Source Type: research
